![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00723645 |
This is an observational, multicenter, nationwide study where information will be collected on the follow-up of patients with chronic hepatitis C who have a viral response at the end of treatment with peginterferon alfa-2b plus ribavirin (administered according to the directions on the products' labeling). No administration of treatment is planned as a result of study enrollment.
Condition | Intervention |
---|---|
Hepatitis C, Chronic Hepacivirus |
Biological: Peginterferon alfa-2b (SCH 54031) Drug: Ribavirin (SCH 18908) |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-Life Clinical Practice in Spanish Hospitals (FAST-4) |
Estimated Enrollment: | 600 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Group 1
Adult subjects with chronic hepatitis C who were treated for the first time with peginterferon alfa-2b plus ribavirin and achieved end-of-treatment response.
|
Biological: Peginterferon alfa-2b (SCH 54031)
Information will be collected on the follow-up of patients with chronic hepatitis C who have a viral response at the end of treatment with peginterferon alfa-2b plus ribavirin (administered for 24 or 48 weeks according to the directions on the products' labeling). The treatment period is not part of the study. The study will be conducted during the patient follow-up period after the end of treatment, for up to 72 weeks.
Drug: Ribavirin (SCH 18908)
Information will be collected on the follow-up of patients with chronic hepatitis C who have a viral response at the end of treatment with peginterferon alfa-2b plus ribavirin (administered for 24 or 48 weeks according to the directions on the products' labeling). The treatment period is not part of the study. The study will be conducted during the patient follow-up period after the end of treatment, for up to 72 weeks.
|
Patient enrollment will be sequential to avoid patient selection bias attributable to the investigator. Each site must enroll 7-8 patients to achieve the calculated sample size so that study objectives can be met. Patients will be selected by the investigator during the last days of treatment with peginterferon alfa-2b plus ribavirin. Only those patients with a viral response at the end of treatment who sign the informed consent form are eligible.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Adult subjects with chronic hepatitis C who were treated for the first time with peginterferon alfa-2b plus ribavirin and achieved end-of-treatment response.
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group ) |
Study ID Numbers: | P05181 |
Study First Received: | July 25, 2008 |
Last Updated: | May 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00723645 History of Changes |
Health Authority: | Spain: Spanish Agency of Medicines |
Antimetabolites Interferon-alpha Liver Diseases Hepatitis, Chronic Interferons Ribavirin Hepatitis, Viral, Human Angiogenesis Inhibitors Antiviral Agents |
Hepatitis Virus Diseases Digestive System Diseases Peginterferon alfa-2b Hepatitis C Interferon Alfa-2a Hepatitis C, Chronic Interferon Alfa-2b |
Antimetabolites Anti-Infective Agents Liver Diseases Hepatitis, Chronic Flaviviridae Infections Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Ribavirin Physiological Effects of Drugs Hepatitis, Viral, Human Therapeutic Uses Hepatitis C Angiogenesis Modulating Agents |
Growth Inhibitors RNA Virus Infections Growth Substances Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Virus Diseases Hepatitis Digestive System Diseases Peginterferon alfa-2b Interferon Alfa-2b Hepatitis C, Chronic |